News
EMMA
0.052
NaN%
--
Weekly Report: what happened at EMMA last week (0907-0911)?
Weekly Report · 23m ago
Weekly Report: what happened at EMMA last week (0831-0904)?
Weekly Report · 09/07 09:32
Major Insider Move: CEO Makes Bold Emmaus Life Sciences Stock Purchase
TipRanks · 09/03 02:09
Emmaus Life Sciences enters agreement to evaluate L-glutamine in PDAC
TipRanks · 08/31 13:35
Weekly Report: what happened at EMMA last week (0824-0828)?
Weekly Report · 08/31 09:35
Weekly Report: what happened at EMMA last week (0817-0821)?
Weekly Report · 08/24 09:36
Weekly Report: what happened at EMMA last week (0810-0814)?
Weekly Report · 08/17 09:36
Weekly Report: what happened at EMMA last week (0803-0807)?
Weekly Report · 08/10 09:34
Weekly Report: what happened at EMMA last week (0727-0731)?
Weekly Report · 08/03 09:34
Weekly Report: what happened at EMMA last week (0720-0724)?
Weekly Report · 07/27 09:36
Weekly Report: what happened at EMMA last week (0713-0717)?
Weekly Report · 07/20 09:34
Weekly Report: what happened at EMMA last week (0706-0710)?
Weekly Report · 07/13 09:35
Weekly Report: what happened at EMMA last week (0629-0703)?
Weekly Report · 07/06 09:36
Weekly Report: what happened at EMMA last week (0622-0626)?
Weekly Report · 06/29 09:34
Weekly Report: what happened at EMMA last week (0615-0619)?
Weekly Report · 06/22 09:38
Weekly Report: what happened at EMMA last week (0608-0612)?
Weekly Report · 06/15 09:39
Weekly Report: what happened at EMMA last week (0601-0605)?
Weekly Report · 06/08 09:37
Weekly Report: what happened at EMMA last week (0525-0529)?
Weekly Report · 06/01 09:39
Weekly Report: what happened at EMMA last week (0518-0522)?
Weekly Report · 05/25 09:40
Weekly Report: what happened at EMMA last week (0511-0515)?
Weekly Report · 05/18 09:40
More
Webull provides a variety of real-time EMMA stock news. You can receive the latest news about Emmaus Life Scie through multiple platforms. This information may help you make smarter investment decisions.
About EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.